ACR Meeting Abstracts

ACR Meeting Abstracts

Abstract Number: 1084

COVID-19 Among Patients with Inflammatory Arthropathies Participating in the RHUMADATA Clinical Database and Registry

Denis Choquette1, Louis Bessette2, Loïc Choquette Sauvageau1, Boulos Haraoui1, Isabelle Ferdinand1, Frédéric Massicotte1, Valerie Nadon1, Jean-Pierre Pelletier1, Jean-Pierre Raynauld1, Marie-Anaïs Rémillard1, Diane Sauvageau1, Edith Villeneuve1 and Louis Coupal3, 1Institut de Rhumatologie de Montréal, Montréal, QC, Canada, 2Centre de l'Ostoporose et de Rhumatologie de Qubec, Québec City, QC, Canada, 3Institut de Rhumatologie de Montréal, Saint-Lambert, QC, Canada

Meeting: ACR Convergence 2021

Keywords: ,

Session Information

Date: Monday, November 8, 2021

Title: Miscellaneous Rheumatic & Inflammatory Diseases Poster II: Clinical Features & Diagnostics (1083–1117)

Session Type: Poster Session C

Session Time: 8:30AM-10:30AM

Background/Purpose: The COVID-19 pandemic has hit the world since 2019. The province of Québec in Canada has not escaped this plague. Our goal is to compare inflammatory arthropathies patients with and without COVID-19 and compare the cumulative rate of COVID-19 infections in our cohort to that of reference populations.

Methods: RHUMADATA® clinical database and registry collect patient data that includes socio-demographics, patient-reported outcomes, disease activity indices, laboratory variables, clinical exam data, concomitant medications, inflammatory disease treatments, comorbidities, and infections. Patients followed either in person or by phone were systematically asked about their COVID-19 status since March 2019. More specifically, patients were asked about signs and symptoms of COVID-19, actual positive/negative test results and history of contact and travels. We matched four patients without COVID-19 (controls) to each patient with COVID-19. The matching was made based on primary diagnosis, gender, age at diagnosis, and year of last treatment. The analyses were performed on data extracted on May 11, 2021. We used the number of reported COVID-19 infections to develop estimates of the burden of infection in our cohort. We further compared these estimates to that of reference populations.

Results: Fifty-four patients are known to have had COVID-19 in the RHUMADATA cohort. The crude rate of confirmed COVID- 19 cases among active RHUMADATA patients is estimated at 1324 per 100,000 (95% CI = [1021,1715]) or alternatively 13.9 cases per 1000 person-years of follow-up (95% CI = [10.5,18.0]). The treatment, clinical, and comorbidity profiles of patients with COVID-19 were like their matched controls. Overall, most subjects were women (68%). Three deaths were observed in our cohort; two occurred in the COVID-19 group and were attributed to COVID-19. As of May 27, 2021, the estimated cumulative rate of confirmed COVID-19 cases in the province of Québec is 4302 per 100,000, the second-highest rate among Canadian provinces. The reported rates from “local service networks” located around Montréal (Montréal, Laval, Montérégie) ranged from 2573 to 9214 cases per 100,000.

A matched cohort study using national Veterans Affairs data compared COVID-19 rates of RA and non-RA patients (1). Estimated rates were of 27.3 [25.5, 29.2] and 20.5 [ 19.0, 22.1] per 1000 person-years.

A recent seroprevalence study produced by Héma Québec estimated that 15% of the Québec population developed COVID-19 antibodies (10% because of an infection and 5% due to vaccination).

Conclusion: The rate of COVID-19 infections in the RHUMADATA cohort is lower than rates observed in the general population in the region of Montreal and among VA RA and non-RA patients. These differences may result from under-reporting, gender-ethnic-cultural differences, adherence to protective measures due to efficacy beliefs, and methodological differences.

1. England et al. (2021), Risk of COVID-19 in Rheumatoid Arthritis: A National Veterans Affairs Matched Cohort Study in At-Risk Individuals. Arthritis & Rheumatology. Accepted Author Manuscript.

2. Press release accessed at https://www.hema-quebec.qc.ca on May 27, 2021.

Disclosures: D. Choquette, AbbVie, 2, 5, Amgen, 2, 5, Celltrion, 2, Eli Lilly, 2, Novartis, 2, 5, Pfizer Inc, 2, 5, Sandoz, 2, 5, Sanofi, 2, 5, Teva Pharmaceuticals, 2, Gilead Sciences, 2; L. Bessette, Amgen, 2, 5, 6, Bristol-Myers Squibb, 2, 5, 6, Janssen, 2, 5, 6, Roche, 2, 5, 6, UCB, 2, 5, 6, AbbVie, 2, 5, 6, Pfizer, 2, 5, 6, Merck & Co, 2, 5, Celgene, 2, 5, 6, Sanofi, 2, 5, 6, Eli Lilly, 2, 5, 6, Novartis, 2, 5, 6, Gilead, 2, 5, 6, Sandoz, 2, 5, 6, Teva, 2, 6; L. Choquette Sauvageau, None; B. Haraoui, Amgen Inc., 2, 6, AbbVie, 2, 6, Bristol-Myers Squibb, 2, 6, Eli Lilly, 2, 6, Janssen, 2, 6, Merck, 2, 6, UCB, 2, 6, Celgene, 2, 6, Novartis, 2, 6, Pfizer, 2, 6, Roche, 2, 6, Sandoz, 2, 6, Sanofi-Genzyme, 2, 6; I. Ferdinand, AbbVie, 2, Amgen, 2, 6, Novartis, 2, Pfizer, 2, 6; F. Massicotte, AbbVie, 2, Pfizer, 2, Janssen, 2, 6, Eli Lilly, 2; V. Nadon, None; J. Pelletier, ArthroLab Inc., 8, TRB Chemedica SA, 2, 5; J. Raynauld, ArthroLab Inc., 2; M. Rémillard, AbbVie, 2, 6, Amgen, 2, 6, Eli Lilly, 2, 6, Novartis, 2, 6, Pfizer, 2, 6, Sandoz, 2, 6; D. Sauvageau, None; E. Villeneuve, UCB, 2, Celgene, 2, Roche, 2, 6, Pfizer, 2, 6, Amgen, 2, AbbVie, 2, 6, Sanofi-Genzyme, 2; L. Coupal, None.

To cite this abstract in AMA style:

Choquette D, Bessette L, Choquette Sauvageau L, Haraoui B, Ferdinand I, Massicotte F, Nadon V, Pelletier J, Raynauld J, Rémillard M, Sauvageau D, Villeneuve E, Coupal L. COVID-19 Among Patients with Inflammatory Arthropathies Participating in the RHUMADATA Clinical Database and Registry [abstract]. Arthritis Rheumatol. 2021; 73 (suppl 9). https://acrabstracts.org/abstract/covid-19-among-patients-with-inflammatory-arthropathies-participating-in-the-rhumadata-clinical-database-and-registry/. Accessed .

« Back to ACR Convergence 2021

ACR Meeting Abstracts - https://acrabstracts.org/abstract/covid-19-among-patients-with-inflammatory-arthropathies-participating-in-the-rhumadata-clinical-database-and-registry/